Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating restated by analysts at N+1 Singer in a research report issued on Monday.
Separately, Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 271 ($3.54) price target on shares of Ergomed PLC in a research note on Friday, September 2nd.
Ergomed PLC (LON:ERGO) opened at 123.00 on Monday. Ergomed PLC has a 52-week low of GBX 117.00 and a 52-week high of GBX 173.74. The stock has a 50 day moving average of GBX 120.00 and a 200 day moving average of GBX 135.41. The stock’s market capitalization is GBX 35.36 million.
About Ergomed PLC
Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs.
Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with MarketBeat.com's FREE daily email newsletter.